Quinn Thomas J, Rajagopalan Malolan S, Gill Beant, Mehdiabadi Shabnam M, Kabolizadeh Peyman
Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA.
Mount Carmel, Radiology, Inc., Columbus, OH, USA.
J Gastrointest Oncol. 2020 Feb;11(1):1-12. doi: 10.21037/jgo.2019.10.02.
The standard of care in locally advanced rectal cancer is preoperative chemoradiation followed by surgical resection. However, the optimal treatment paradigm is currently controversial for patients with pathological T3N0 (pT3N0) in the era of total mesorectal excision (TME). Given the paucity of data, we conducted an analysis using the National Cancer Database (NCDB) to identify patterns of care and outcomes.
We utilized the NCDB to identify 7,836 non-metastatic, pT3N0 rectal cancer patients who did not receive neoadjuvant therapy from 2004-2014. Univariate and multivariable analysis for factors affecting treatment selection were completed using logistic regression. Overall survival (OS) analyses were completed using Cox regression modeling, incorporating propensity scores with inverse probability of treatment weighting (IPTW) and conditional landmark analysis.
There was a significant improvement in OS in patients receiving adjuvant chemotherapy (P<0.01) or radiotherapy (RT) with chemotherapy (P<0.01) observation alone. There was no significant difference between RT observation (P=0.54) and chemotherapy chemotherapy with RT cohorts (P=0.15). Multivariable analysis showed age, gender, race, insurance status, income, Charlson-Deyo Comorbidity Condition (CDCC) score, facility location, grade, surgical margin, RT, and chemotherapy to be statistically significant predictors of OS. After correcting for indication and immortal time biases, chemotherapy, with or without RT, improved OS compared with observation [hazard ratio (HR) 0.48, P<0.001]. This benefit was maintained in the margin negative cohort.
Practice patterns vary in the management of pT3N0 rectal cancer patients. This analysis suggests that the use of adjuvant therapy, particularly adjuvant chemotherapy with or without RT, appears to improve OS.
局部晚期直肠癌的标准治疗方案是术前放化疗后行手术切除。然而,在全直肠系膜切除术(TME)时代,对于病理分期为T3N0(pT3N0)的患者,最佳治疗模式目前仍存在争议。鉴于数据有限,我们利用国家癌症数据库(NCDB)进行了一项分析,以确定治疗模式和结局。
我们利用NCDB识别出2004年至2014年间7836例未接受新辅助治疗的非转移性pT3N0直肠癌患者。使用逻辑回归对影响治疗选择的因素进行单变量和多变量分析。使用Cox回归模型进行总生存(OS)分析,纳入倾向评分并采用治疗权重逆概率(IPTW)和条件地标分析。
接受辅助化疗(P<0.01)或放疗(RT)联合化疗(P<0.01)的患者的OS有显著改善,单纯观察的患者则无。RT联合观察组(P=0.54)与化疗联合RT组(P=0.15)之间无显著差异。多变量分析显示,年龄、性别、种族、保险状况、收入、Charlson-Deyo合并症状况(CDCC)评分、医疗机构位置、分级、手术切缘、RT和化疗是OS的统计学显著预测因素。校正指征和永生时间偏倚后,与观察相比,化疗(无论是否联合RT)可改善OS[风险比(HR)0.48,P<0.001]。在切缘阴性队列中,这种获益得以维持。
pT3N0直肠癌患者的治疗模式存在差异。该分析表明,辅助治疗的使用,尤其是联合或不联合RT的辅助化疗,似乎可改善OS。